Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Eli Lilly and Company (LLY)

372.135   -2.625 (-0.7%) 12-05 12:18
Open: 373.76 Pre. Close: 374.76
High: 375.25 Low: 369.445
Volume: 862,386 Market Cap: 353,594(M)

Technical analysis

as of: 2022-12-05 11:50:00 AM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 438.29     One year: 511.92
Support: Support1: 353.53    Support2: 340.11
Resistance: Resistance1: 375.25    Resistance2: 438.29
Pivot: 363.26
Moving Average: MA(5): 370.55     MA(20): 363.24
MA(100): 331.09     MA(250): 301.35
MACD: MACD(12,26): 6.5     Signal(9): 6.2
Stochastic oscillator: %K(14,3): 92.7     %D(3): 91.1
RSI: RSI(14): 64
52-week: High: 375.25  Low: 231.86
Average Vol(K): 3-Month: 3,015 (K)  10-Days: 1,850 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LLY ] has closed below upper band by 14.8%. Bollinger Bands are 6.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 375.39 - 377.21 377.21 - 378.78
Low: 360.67 - 362.76 362.76 - 364.56
Close: 371.59 - 374.87 374.87 - 377.71

Company Description

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Headline News

Mon, 05 Dec 2022
SPYG, GOOGL, LLY, TMO: Large Inflows Detected at ETF - Nasdaq

Mon, 05 Dec 2022
Is Johnson & Johnson Stock A Better Pick Over Its Peer? - Forbes

Mon, 05 Dec 2022
Eli Lilly and Company (NYSE:LLY) Short Interest Down 8.0% in November - MarketBeat

Mon, 05 Dec 2022
Even After This Year's Melt-Up, Runway Remains for LLY Stock - InvestorPlace

Wed, 23 Nov 2022
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Mon, 21 Nov 2022
Eli Lilly Stock: Don't Take This Medicine (NYSE:LLY) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 957 (M)
Shares Float 948 (M)
% Held by Insiders 0.2 (%)
% Held by Institutions 84 (%)
Shares Short 5,420 (K)
Shares Short P.Month 5,330 (K)

Stock Financials

EPS 6.67
EPS Est Next Qtl 1.09
EPS Est This Year 4.19
EPS Est Next Year 4.63
Book Value (p.s.) 7.59
Profit Margin (%) 19.5
Operating Margin (%) 30.3
Return on Assets (ttm) 11.6
Return on Equity (ttm) 74.2
Qtrly Rev. Growth -3.8
Gross Profit (p.s.) 22.31
Sales Per Share 30.38
EBITDA (p.s.) 10.89
Qtrly Earnings Growth -31.4
Operating Cash Flow 7,110 (M)
Levered Free Cash Flow 4,990 (M)

Stock Valuations

PE Ratio 55.82
PEG Ratio 2.5
Price to Book value 49.12
Price to Sales 12.27
Price to Cash Flow 50.16

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2022-03-09
Ex-Dividend Date 2022-02-13
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.